Role of androgens in epilepsy

Expert Review of Neurotherapeutics

Volumn 6, Issue 7, 2006, Pages 1061-1075

  Frye, Cheryl A ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

aminobutyric acidA receptors; Affect; Allopregnanolone; Antiepileptic drugs; Anxiety; Drug metabolism; Estrogen; Gonadal hormones

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR; STEROID; STEROID RECEPTOR;

COGNITION; DRUG MECHANISM; ENDOCRINE DISEASE; EPILEPSY; HUMAN; REVIEW; SEIZURE; STEROID RELEASE;

ANDROGENS; ANIMALS; ANTICONVULSANTS; BRAIN; EPILEPSY; FEMALE; HUMANS; MALE; MODELS, NEUROLOGICAL; TREATMENT OUTCOME;

EID: 33745965329     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.7.1061     Document Type: Review

References (172)

1. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin. Proc. 71(6), 576-586 (1996).
2. Begley CE, Famular M, Annegers JF et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia. 41, 342-351 (2000).
3. Kadir ZA, Chadwick DW. Principles of treatment of epilepsy. Drugs Today 1, 35-41 (1999).
4. Silverman A, Livne I, Witkin JW. The gonadatropin-releasing hormone (GnRH) neuronal systems: immunocytochemistry and in situ hybridization. In: The Physiology of Reproduction. Knobil E, Neill JD (Eds), 1683-1709 (1994).
5. Everett JW. Pituitary and hypothalamus: perspectives and overview. In: The Physiology of Reproduction. Knobil E, Neill JD, (Eds), Raven Press, NY, USA 1509-1526 (1994).
6. Baulieu EE, Robel P, Schumacher M. Neurosteroids: beginning of the story. Int. Rev. Neurobiol. 46, 1-32 (2001).
7. Bloch M, Rubinow DR, Berlin K, Kevala KR, Kim HY, Schmidt PJ. Monoamines and neurosteroids in sexual function during induced hypogonadism in healthy men. Arch. Gen. Psychiatry 63, 450-456 (2006).
8. Mensah-Nyagan G, Do-Rego JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H. Regulation of neurosteroid biosynthesis in the frog diencephalon by GABA and benzodiazepines. Horm. Behav. 40, 218-225 (2001).
9. Brambilla F, Biggio G, Pisu MG et al. Plasma concentrations of anxiolytic neurosteroids in men with normal anxiety scores: a correlation analysis. Neuropsychobiology 50, 6-9 (2004).
10. Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 6, 2311-2322 (1992).
11. Patchev VK, Almeida OF. Gonadal steroids exert facilitating and "buffering" effects on glucocorticoid-mediated transcriptional regulation of corticotropin-releasing hormone and corticosteroid receptor genes in rat brain. J. Neurosci. 16, 7077-7084 (1996).
12. Barbaccia ML, Serra M, Purdy RH, Biggio G. Stress and neuroactive steroids. Int. Rev. Neurobiol. 46, 243-272 (2001).
13. Frye CA, Rhodes ME, Petralia SM, Walf AA, Sumida K, Edinger KL. 3e-hydroxy-5e-pregnan-20-one in the midbrain ventral tegmental area mediates social, sexual, and affective behaviors. Neuroscience 38, 1007-1014 (2006).
14. Schumacher M, Weill-Engerer S, Liere P et al. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog. Neurobiol. 71, 3-29 (2003).
15. Grosso S, Luisi S, Mostardini R et al. Interictal and post-ictal circulating levels of allopregnanolone, an anticonvulsant metabolite of progesterone, in epileptic children. Epilepsy Res. 54, 29-34 (2003).
16. Gray GD. Changes in the levels of luteinizing hormone and testosterone in the circulation of ageing male rats. J. Endocrinol. 76, 551-552 (1978).
17. Chambers KC, Phoenix CH. Testosterone and the decline of sexual behavior in aging male rats. Behav. Neural. Biol. 40, 87-97 (1984).
18. Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 61, S2-S15 (2003).
19. Nemeroff CB. NeuroEndocrinology. CRC Press, Ann Arbor, MI, USA 1-512 (1992)
20. Harden CL, Baker GA, Frye CA, Montouris GD, Pennell PB, Zupanc ML. Epilepsy and ovarian hormones. Neurology (Suppl.) 1-16 (2005).
21. Beyenburg S, Stoffel-Wagner B et al. Neuroactive steroids and seizure susceptibility. Epilepsy Res. 44, 141-153 (2001).
22. Terasawa E, Timiras PS. Electrical activity during the estrous cycle of the rat: cyclic changes in limbic structures. Endocrinology 83, 207-216 (1968).
23. Frye CA, Rhodes ME. Estrogen-priming can enhance progesterone's antiseizure effects in part by increasing hippocampal levels of allopregnanolone. Pharmacol. Biochem. Behav. 81, 907-916 (2005).
24. Schwartz-Giblin S, Korotzer A, Pfaff DW. Steroid hormone effects on picrotoxin-induced seizures in female and male rats. Brain Res. 476, 240-247 (1989).
25. Veliskova J, Velisek L, Galanopoulou AS, Sperber EF. Neuroprotective effects of estrogens on hippocampal cells in adult female rats after status epilepticus. Epilepsia. 41(Suppl. 6), S30-S35 (2000).
26. Bäckstrom T, Zetterlund B, Blom S, Romano M. Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol. Scand. 69, 240-248 (1984).
27. Rhodes ME, Harney JP, Frye CA. Gonadal, adrenal, and neuroactive steroids' role in ictal activity. Brain Res. 1000, 8-18 (2004).
28. Scharfman HE. Absence of information about hormones and absence. Epilepsy Curr. 5, 101-103 (2005).
29. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 38, 1082-1088 (1997).
30. Harden CL, Pulver MC, Ravdin L, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia. 40, 1402-1407 (1999).
31. Edwards HE, Burnham WM, Mendonca A, Bowlby DA, MacLusky NJ. Steroid hormones affect limbic afterdischarge thresholds and kindling rates in adult female rats. Brain Res. 38, 136-150 (1999).
32. Kalkbrenner KA, Standley CA. Estrogen modulation of NMDA-induced seizures in ovariectomized and non-ovariectomized rats. Brain Res. 964, 244-249 (2003).
33. Scharfman HE, Goodman JH, Rigoulot MA et al. Seizure susceptibility in intact and ovariectomized female rats treated with the convulsant pilocarpine. Exp. Neurol. 196, 73-86 (2005).
34. Scharfman HE, Maclusky NJ. Similarities between actions of estrogen and BDNF in the hippocampus: coincidence or clue? Trends Neurosci. 28, 79-85 (2005).
35. Cheng YJ, Karavolas HJ. Conversion of progesterone to 5e-pregnane3,20-dione and 3e-hydroxy-5e-pregnan-20-one by rat medical basal hypothalami and the effects of estradiol and stage of estrous cycle on the conversion. Endocrinology 93, 1157-1162 (1973).
36. Vongher JM, Frye CA. Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol. Biochem. Behav. 64, 777-785 (1999).
37. Herzog AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 45, 1660-1662 (1995).
38. Frye CA, Bayon LE. Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3e,5e-THP. Neuroendocrinol. 68, 272-280 (1998).
39. Frye CA, Bayon LE. Cyclic withdrawal from endogenous and exogenous progesterone increases kainic acid and perforant pathway induced seizures. Pharmacol. Biochem. Behav. 62, 315-321 (1999).
40. Frye CA, Scalise TJ. Antiseizure effects of progesterone and 3α,5α-THP in kainic acid and perforant pathway models of epilepsy. Psycho. Neuroendocrinol. 4, 407-420 (2000).
41. Hoffman GE, Moore N, Fiskum G, Murphy AZ. Ovarian steroid modulation of seizure severity and hippocampal cell death after kainic acid treatment. Exp. Neurol. 182, 124-134 (2003).
42. Ruusa J, Bergman B. Sex hormones and alcohol withdrawal: does a good supply of testosterone prevent serious symptoms during detoxification? Alcohol 13, 139-145 (1996).
43. Badalian LO, Temin PA, Mukhin K. Effect of testenate in the treatment of epilepsy in men. ZH Nevropatol. Psikhiatr. Im. SS Korsakova 91, 44-47 (1991).
44. Herzog AG, Klein P, Jacobs AR. Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism. Neurology 50, 782-784 (1998).
45. Harden C, MacLusky NJ. Aromatase inhibition, testosterone and seizures. Epilepsy Behav. 5, 260-263 (2004).
46. Farwell JR, Blackner G, Sulzbacher S, Adelman L, Voeller M. First febrile seizures. Characteristics of the child, the seizure, and the illness. Clin. Pediatr. 33, 263-267 (1994).
47. A receptor binding. Pharmacol. Biochem. Behav. 43, 441-447 (1992).
48. Pericic D, Manev H, Bujas M. Gonadal hormones and picrotoxin-induced convulsions in male and female rats. Brain Res. 736, 174-179 (1996).
49. Rhodes ME, McCormick CM, Frye CA. 3α,5α-THP mediates progestins' effects to protect against adrenalectomy-induced cell death in the dentate gyrus of female and male rats. Pharmacol. Biochem. Behav. 78, 505-512 (2004).
50. Chakraborty TR, Gore AC. Aging-related changes in ovarian hormones, their receptors, and neuroendocrine function. Exp. Biol. Med. 229, 977-987 (2004).
51. Edwards HE, Burnham WM, MacLusky NJ. Testosterone and its metabolites affect afterdischarge thresholds and the development of amygdala kindled seizures. Brain Res. 838(1-2), 151-157 (1999).
52. Pesce ME, Acevedo X, Pinardi G, Miranda HF. Gender differences in diazepam withdrawal syndrome in mice. Pharmacol. Toxicol. 75, 353-355 (1994).
53. Frye CA, Reed TA. Androgenic neurosteroids: antiseizure effects in an animal model of epilepsy. Psycho. Neuroendocrinol. 23, 385-399 (1998).
54. Kaminski RM, Marini H, Kim WJ, Rogawski MA. Anticonvulsant activity of androsterone and etiocholanolone. Epilepsia 46, 819-827 (2005).
55. Reddy DS. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3e-androstanediol and 17f-estradiol. Neuroscience 129, 195-207 (2004).
56. Iswari S, Colas AE, Karavolas HJ. Binding of 5e-dihydroprogesterone and other progestins to female rat anterior pituitary nuclear extracts. Steroids 47, 189-203 (1986).
57. Smith HE, Smith RG, Toft DO, Neergaard JR, Burrows EP, O'Malley BW. Binding of steroids to progesterone receptor proteins in chick oviduct and human uterus. J. Biol. Chem. 249, 5924-5932 (1974).
58. Roselli CE, Handa RJ, Resko JA. Quantitative distribution of nuclear androgen receptors in microdissected areas of the rat brain. Neuroendocrinology 49, 449-453 (1989).
59. Harding SM, McGinnis MY. Androgen receptor blockade in the MPOA or VMN: effects on male sociosexual behaviors. Physiol. Behav. 81, 671-680 (2004).
60. Brown TJ, Adler GH, Sharma M, Hochberg RB, MacLusky NJ. Androgen treatment decreases estrogen receptor binding in the ventromedial nucleus of the rat brain: a quantitative in vitro autoradiographic analysis. Mol. Cell Neurosci. 5, 549-555 (1994).
61. Lieberburg I, MacLusky N, McEwen BS. Cytoplasmic and nuclear estradiol-17β binding in male and female rat brain: regional distribution, temporal aspects and metabolism. Brain Res. 193, 487-503 (1980).
62. Kuiper GG, Lemmen JG, Carlsson B et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139, 4252-4263 (1998).
63. Pak TR, Chung WC, Lund TD, Hinds LR, Clay CM, Handa RJ. The androgen metabolite, 5e-androstane-3f.17f-diol (3f-Adiol), is a potent modulator of estrogen receptor-β1-mediated gene transcription in neuronal cells. Endocrinology 146, 147-155 (2005).
64. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERf, AR, 5e-androstane-3f, 17f-diol, and CYP7B1, regulates prostate growth. Proc. Natl Acad. Sci. USA 99,13589-13594 (2002).
65. Kuiper TB, Langer WD, Velusamy T. Evolutionary status of the pre-protostellar core L1498. Astrophys. J. 468, 761-773 (1996).
66. Tremblay GB, Tremblay A, Copeland NG et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol. Endocrinol. 11, 353-365 (1997).
67. Green S, Walter P, Kumar V et al. Human oestrogen receptor cDNA: sequence, expression and homology to ERf-e. Nature 320, 134-139 (1986).
68. Kuiper GG, Carlsson B, Grandien K et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870 (1997).
69. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 2771, 508-510 (1997).
70. Tena-Sempere M, Navarro VM, Mayen A, Bellido C, Sanchez-Criado JE. Regulation of estrogen receptor (ER) isoform messenger RNA expression by different ER ligands in the female rat pituitary. Biol. Reprod. 70, 671-678 (2004).
71. Shughrue P, Scrimo P, Lane M, Askew R, Merchenthaler I. The distribution of estrogen receptor-β mRNA in forebrain regions of the estrogen receptor-α knockout mouse. Endocrinology 138, 5649-5652 (1997).
72. Melcangi RC, Magnaghi V, Galbiati M, Martini L. Formation and effects of neuroactive steroids in the central and peripheral nervous system. Int. Rev. Neurobiol. 46, 145-176 (2001).
73. Engel SR, Grant KA. Neurosteroids and behavior. Int. Rev. Neurobiol. 46, 321-348 (2001).
74. Frye CA, Manjarrez J, Camacho-Arroyo I. Infusion of 3α,5α-THP to the pontine reticular formation attenuates PTZ-induced seizures. Brain Res. 881, 98-102 (2000).
75. Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann. Neurol. 53, 390-391 (2003).
76. Rhodes ME, Frye CA. Progestins in the hippocampus of female rats have antiseizure effects in a pentylenetetrazole seizure model. Epilepsia 45, 1531-1538 (2004).
77. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232, 1004-1007 (1986).
78. Rosciszewska D, Buntner B, Guz I, Zawisza L. Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J. Neurol. Neurosurg. Psychiatry 49, 47-51 (1986).
79. Frye CA, Scalise TJ, Bayon LE. Finasteride blocks the reduction in ictal activity produced by exogenous estrous cyclicity. J. Neuroendocrinol. 10, 291-296 (1998).
80. Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA. Finasteride. A 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J. Pharmacol. Exp. Ther. 288, 679-684 (1999).
81. Frye CA, Rhodes ME, Walf A, Harney J. Progesterone reduces pentylenetetrazolinduced ictal activity of wild-type mice but not those deficient in type I 5α-reductase. Epilepsia 5, 14-17 (2002).
82. Gee KW. Steroid modulation of the GABA/benzodiazepine receptor-linked chloride ionophore. Mol. Neurobiol. 2, 291-317 (1988).
83. Frye CA, Duncan JE, Basham M, Erskine MS. Behavioral effects of 3 α-androstanediol. II: Hypothalamic and preoptic area actions via a GABAergic mechanism. Behav. Brain Res. 79, 119-130 (1996).
84. Frye CA, Van Keuren KR, Erskine MS. Behavioral effects of 3 α-androstanediol. I: Modulation of sexual receptivity and promotion of GABA-stimulated chloride flux. Behav. Brain Res. 79, 109-118 (1996).
85. Frye CA, Rhodes ME, Walf AA, Harney JP. Testosterone reduces pentylenetetrazoleinduced ictal activity of wild-type mice but not those deficient in type I 5α-reductase. Brain Res. 918, 182-186 (2001).
86. Edeh J, Toone B. Relationship between interictal psychopathology and the type of epilepsy. Results of a survey in general practice. Br. J. Psychiatry 151, 95-101 (1987).
87. Gilliam F, Hecimovic H, Sheline Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav. 4, 26-30 (2003).
88. Gureje O. Interictal psychopathology in epilepsy. Prevalence and pattern in a Nigerian clinic. Br. J. Psychiatry 158, 700-705 (1991).
89. Hermann BP, Seidenberg M, Bell B. Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia. 41, 31-41 (2000).
90. Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia. 37, 148-161 (1996).
91. Manchanda R, Schaefer B, McLachlan RS et al. Psychiatric disorders in candidates for surgery for epilepsy. J. Neurol. Neurosurg. Psychiatry 61, 82-89 (1996).
92. Pariente PD, Lepine JP, Lellouch J. Lifetime history of panic attacks and epilepsy: an association from a general population survey. J. Clin. Psychiatry 52, 88-89 (1991).
93. Perini GI, Tosin C, Carraro C et al. Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy. J. Neurol. Neurosurg. Psychiatry 61, 601-605 (1996).
94. Scicutella A, Ettinger BA. Treatment of anxiety in epilepsy. Epilepsy Behav. 5, 10-12 (2002).
95. Adamec RE. Amygdala kindling and anxiety in the rat. Neuroreport 1, 255-258 (1990).
96. Swanson SJ, Rao SM, Grafman J, Salazar AM, Kraft J. The relationship between seizure subtype and interictal personality. Results from the Vietnam Head Injury Study. Brain 118, 91-103 (1995).
97. Erdogan F, Golgeli A, Arman F, Ersoy AO. The effects of pentylenetetrazole-induced status epilepticus on behavior, emotional memory, and learning in rats. Addict Behav. 5, 388-393 (2004).
98. File SE, Lister RG. Do the reductions in social interaction produced by picrotoxin and pentylenetetrazole indicate anxiogenic actions? Neuropharmacology 23(7A), 793-796 (1984).
99. Szyndler J, Rok P, Maciejak P et al. Effects of pentylenetetrazol-induced kindling of seizures on rat emotional behavior and brain monoaminergic systems. Pharmacol. Biochem. Behav. 73, 851-861 (2002).
100. File SE, Mabbutt PS, Becker A, Gonzalez LE, Fluck E. Short-term rebound anxiolytic effects and long-term changes in platelet benzodiazepine binding after pentylenetetrazole-kindling in two strains of rat. Anxiety 2, 109-116 (1996).
101. Devinsky O. Introduction: managing epilepsy in special populations. Rev. Neurol. Dis. 1, 3 (2004).
102. Abrahams S, Morris RG, Polkey CE et al. Hippocampal involvement in spatial and working memory: a structural MRI analysis of patients with unilateral mesial temporal lobe sclerosis. Brain Cogn. 41, 39-65 (1999).
103. Helmstaedter C. Effects of chronic epilepsy on declarative memory systems. Prog. Brain Res. 135, 439-453 (2002).
104. Collier TJ, Routtenberg A. Selective impairment of declarative memory following stimulation of dentate gyrus granule cells: a naloxone-sensitive effect. Brain Res. 310, 384-387 (1984).
105. Mathern GW, Adelson PD, Cahan LD, Leite JP. Hippocampal neuron damage in human epilepsy: Meyer's hypothesis revisited. Prog. Brain Res. 135, 237-251 (2002).
106. Mello LE, Cavalheiro EA, Tan AM et al. Circuit mechanisms of seizures in the pilocarpine model of chronic epilepsy: cell loss and mossy fiber sprouting. Epilepsia 34, 985-995 (1993).
107. Schwarcz R, Zaczek R, Coyle JT. Microinjection of kainic acid into the rat hippocampus. Eur. J. Pharmacol. 50, 209-220 (1978).
108. Franke H, Kittner H. Morphological alterations of neurons and astrocytes and changes in emotional behavior in pentylenetetrazol-kindled rats. Pharmacol. Biochem. Behav. 70, 291-303 (2001).
109. Sloviter RS. "Epileptic" brain damage in rats induced by sustained electrical stimulation of the perforant path. I. Acute electrophysiological and light microscopic studies. Brain Res. Bull. 10, 675-697 (1983).
110. Kotloski R, Lynch M, Lauersdorf S, Sutula T. Repeated brief seizures induce progressive hippocampal neuron loss and memory deficits. Prog. Brain Res. 135, 95-110 (2002).
111. Grecksch U, Becker A, Gadau C, Matthies H. Gangliosides improve a memory deficit in pentylentetrazol-kindled rats. Pharmacol. Biochem. Behav. 39, 825-828 (1991).
112. Genkova-Papazova M, Lazarova-Bakarov M. Pentylenetetrazole kindling impairs long-term memory in rats. Eur. Neuropsychopharmacol. 5, 53-56 (1995).
113. Genkova-Papazova B, Petkova N, Shishkova M, Lazarova-Bakarova MG. The GABA-B antagonist CGP 36742 prevent PTZ-kindling-provoked amnesia in rats. Eur. Neuropsychopharmacol. 10, 273-278 (2000).
114. Morrell MJ. Epilepsy in women: the science of why it is special. Neurology 53, S42-S48 (1999).
115. Morrell MJ. Hormones and epilepsy through the lifetime. Epilepsia 33, S49-S61 (1992).
116. Trimble MR. Serum prolactin in epilepsy and hysteria. Br. Med. J. 2, 1682 (1978).
117. Pritchard PB 3rd, Wannamaker BB, Sagel J, Nair R, DeVillier C. Endocrine function following complex partial seizures. Ann. Neurol. 14, 27-32 (1983).
118. Dana-Haeri J, Trimble M, Oxley J. Prolactin and gonadotrophin changes following generalised and partial seizures. J. Neurol. Neurosurg. Psychiatry 46, 331-335 (1983).
119. Bilo L, Meo R, Valentino R, Buscaino GA, Striano S, Nappi C. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil. Steril. 55, 705-711 (1991).
120. Drislane FW, Coleman AE, Schomer DL et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology 44, 306-310 (1994).
121. Herzog AG, Drislane FW, Schomer DL, et al. Abnormal pulsatile secretion of luteinizing hormone in men with epilepsy: relationship to laterality and nature of paroxysmal discharges. Neurology 40, 1557-1561 (1990).
122. Molaie M, Culebras A, Miller M. Effect of interictal epileptiform discharges on nocturnal plasma prolactin concentrations in epileptic patients with complex partial seizures. Epilepsia 27, 724-728 (1986).
123. Cerullo A, Tinuper P, Provini F et al. Autonomic and hormonal ictal changes in gelastic seizures from hypothalamic hamartomas. Electroencephalogr. Clin. Neurophysiol. 107, 317-322 (1998).
124. Herzog AG, Coleman AE, Jacobs AR et al. Relationship of sexual dysfunction to epilepsy laterality and reproductive hormone levels in women. Epilepsy Behav. 4, 407-413 (2003).
125. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch. Neurol. 43, 347-350 (1986).
126. Bauer J, Isojarvi JI, Herzog AG et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J. Neurol. Neurosurg. Psychiatry 73, 121-125 (2002).
127. Bilo L, Meo R, Valentino R, Di Carlo C, Striano S, Nappi C. Characterization of reproductive endocrine disorders in women with epilepsy. J. Clin. Endocrinol. Metab. 86, 2950-2956 (2001).
128. Herzog AG. Altered reproductive endocrine regulation in men with epilepsy: implications for reproductive function and seizures. Ann. Neurol. 51, 539-542 (2002).
129. Crowley WF Jr, Filicori M, Spratt DI, Santoro NF. The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Prog. Horm. Res. 41, 473-531 (1985).
130. Isojarvi JI, Lofgren E, Juntunen KS et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 62, 247-253 (2004).
131. Herzog AG, Drislane FW, Schomer DL et al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 65, 1016-1020 (2005).
132. Edwards HE, MacLusky NJ, Burnham WM. The effect of seizures and kindling on reproductive hormones in the rat. Neurosci. Biobehav. Rev. 24, 753-762 (2000).
133. Amado D, Cavalheiro EA, Bentivoglio M. Epilepsy and hormonal regulation: the patterns of GnRH and galanin immunoreactivity in the hypothalamus of epileptic female rats. Epilepsy Res. 14, 149-159 (1993).
134. Friedman MN, Geula C, Holmes GL, Herzog AG. GnRH-immunoreactive fiber changes with unilateral amygdala-kindled seizures. Epilepsy Res. 52, 73-77 (2002).
135. Edwards HE, Burnham WM, MacLusky NJ. Testosterone and its metabolites affect afterdischarge thresholds and the development of amygdala kindled seizures. Brain Res. 838, 151-157 (1998).
136. Locock C. Analysis of fifty-two cases of epilepsy observed by the author. Lancet 527-528 (1857).
137. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40, 590-600 (1999).
138. Besag FMC. Behavioural effects of the newer antiepileptic drugs: an update. Exp. Opin. Drug Saf. 3, 1-8 (2004).
139. Boylan LS, Boylan O, Devinsky JJ, Barry TA. Psychiatric uses of antiepileptic treatments. Epilepsy Behav. 3, 54 (2002).
140. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10, 685 (2004).
141. Griffith NM, Szaflarski JP, Szaflarski M et al. Measuring depressive symptoms among treatment-resistant seizure disorder patients: POMS Depression scale as an alternative to the BDI-II. Epilepsy Behav. 7, 266-272 (2005).
142. Schachter SC. Improving quality of life beyond seizure control. Epileptic Disord. 7, 34-38 (2005).
143. Calabrese JR, Calabrese CL, Bowden GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 60, 79-88 (1999).
144. Gilliam FG, Santos J, Vahle V, Carter J, Brown K, Hecimovic H. Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction? Epilepsia. 45, 28-33 (2004).
145. Kanner JJ, Barry AM. Is the psychopathology of epilepsy different from that of nonepileptic patients? Epilepsy Behav. 2, 170-186 (2001).
146. Nagahata M. Neuropsychological and psychiatric problems in epileptic children. No To Hattatsu 22, 143-148 (1990).
147. Stores G. Behavioural effects of antiepileptic drugs. Dev. Med. Child Neurol. 17, 647-658 (1975).
148. Meador KJ, Loring DW, Allen M et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 41, 1537-1540 (1991).
149. Meador KJ, Loring DW, Abney OL et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 34, 153-157 (1993).
150. Meador KJ, Loring DW, Moore EE et al. Comparative cognitive effects of phenobarbital, phenytoin and valproate in healthy subjects. Neurology 45, 1494-1499 (1995).
151. Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res. 68, 63-67 (2006).
152. Voigt JP, Morgenstern E. Comparative effects of carbamazepine, phenytoin, diazepam and clonazepam on inhibitory avoidance learning in mice. Psychopharmacology (Berl). 108, 131-135 (1992).
153. Connell JM, Rapeport WG, Beastall GH, Brodie MJ. Changes in circulating androgens during short term carbamazepine therapy. Br. J. Clin. Pharmacol. 17, 347-351 (1984).
154. Barragry JM, Makin HL, Trafford DJ, Scott DF. Effect of anticonvulsants on plasma testosterone and sex hormone binding globulin levels. J. Neurol. Neurosurg. Psychiatry 41, 913-914 (1978).
155. Toone BK, Wheeler M, Nanjee M, Fenwick P, Grant R. Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics. J. Neurol. Neurosurg. Psychiatry 46, 824-826 (1983).
156. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2, 404-409 (2003).
157. Harden CL, Baker GA, Frye CA, Montouris GD, Pennell PB, Zupanc ML. Epilepsy and ovarian hormones. Neurology (Suppl.) 16-29 (2005).
158. Pennell PB. Using current evidence in selecting antiepileptic drugs for use during pregnancy. Epilepsy Curr. 5, 45-51 (2005).
159. Isojärvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann. Neurol. 39, 579-584 (1996).
160. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329, 1383-1388 (1993).
161. Isojarvi JI, Pakarinen AJ, Ylipalosaari PJ, Myllyla VV. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch. Neurol. 47, 670-676 (1990).
162. Herzog AG, Drislane FW, Schomer DL, et al. Differential effects of antiepileptic drugs on sexual function and reproductive hormones in men with epilepsy: interim analysis of a comparison between lamotrigine and enzyme-inducing antiepileptic drugs. Epilepsia 45, 764-768 (2004).
163. Murialdo G, Galimberti CA, Fonzi S et al. Sex hormones and pituitary function in male epileptic patients with altered or normal sexuality. Epilepsia 36, 360-365 (1995).
164. Derry PA. Psychological treatment in intractable epilepsy: approaches, evidence, and future directions. Adv. Neurol. 97, 375-380 (2006).
165. Trost LF 3rd, Wender RC, Suter CC et al. National Epilepsy Management Panel. Management of epilepsy in adults. Treatment guidelines. Postgrad. Med. 118, 29-33 (2005).
166. Bäckström T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol. Scand. 54, 321-347 (1976).
167. Shavit G, Lerman P, Korczyn AD, Kivity S, Bechar M, Gitter S. Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 34, 959-961 (1984).
168. Krishnamurthy KB, Schomer DL. Weekly fluctuation and adjustment of antiepileptic drugs to treat catamenial epilepsy. Epilepsia 39, 179 (1998).
169. Tatum WO IV, Liporace J, Benbadis SR, Kaplan PW. Updates on the treatment of epilepsy in women. Arch. Intern. Med. 164, 137-145 (2004).
170. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43, 37-44 (2002).
171. Mellon SH, Griffin LD. Synthesis, regulation, and function of neurosteroids. Endocr. Res. 28, 463 (2002).
172. Uzunova V, Sampson L, Uzunov DP. Relevance of endogenous 3α-reduced neurosteroids to depression and antidepressant action. Psychopharmacology (Berl.) 1-11 (2006).